DSC_5829_10240px

The aim of development and improvement of outcome measures is to evaluate current and future therapies. A correct evaluation of therapeutic efficacy is important. If an outcome measure is not sensitive to changes over time, a true effect could be missed, which would ultimately lead to withholding patients an effective treatment. On the other hand, using the wrong outcome measure may lead to prescribing ineffective treatments, with high costs and unnecessary side effects as a consequence.

In the past years the Peripheral Neuropathy Outcome Measure Standardisation (PeriNomS) study has been conducted. This was a large, international study into outcome measures for immune-mediated neuropathies, such as Guillain-Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), polyneuropathy associated with monoclonal gammopathy (MGUSP) and multifocal motor neuropathy (MMN).
As a result of the PeriNomS study an outcome measure was developed that can be used in all future studies in these diseases. This outcome measure proved to be sensitive to changes over time.
Future studies will also aim at developing comparable outcome measures for other neuromuscular and chronic diseases.